OPC 131461
Alternative Names: OPC-131461Latest Information Update: 15 Nov 2024
Price :
$50 *
At a glance
- Originator Otsuka Pharmaceutical
- Class Heart failure therapies
- Mechanism of Action Vasopressin 1a receptor antagonists; Vasopressin V2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Cardiac oedema
Most Recent Events
- 21 Oct 2024 Otsuka Pharmaceutical completes a phase-II trial in Cardiac oedema (Treatment-experienced) in Japan (PO) (NCT05615363)
- 28 Jun 2024 No recent reports of development identified for phase-I development in Cardiac-oedema(In volunteers) in Japan (PO, Suspension)
- 24 Nov 2022 Otsuka Pharmaceuticals completes a phase I trial in healthy adult male subjects in Japan (jRCT2071200061)